EQS-News: thyssenkrupp nucera Continues Stable Business Development in the Third Quarter and Specifies Outlook for 2024/2025

• Stable operational business development in the third quarter and first nine months of 2024/2025 for thyssenkrupp nucera
• Based on preliminary, unaudited figures, the electrolyzer specialist's order intake in the third quarter was EUR 63 million, sales was EUR 184 million, and earnings before interest and taxes (EBIT) was EUR 0 million
• Refined full-year Group revenue outlook
• Slight increase in EBIT outlook for the Group in fiscal year 2024/2025
• Specification of outlooks for the two segments Green Hydrogen (gH2) and Chlor-Alkali (CA)

Dortmund, 15. July 2025 – Based on preliminary, unaudited figures, thyssenkrupp nucera's operating business remained stable in the third quarter of the current fiscal year 2024/2025. The world's leading provider of electrolysis technologies expects consolidated sales of EUR 184 million (same quarter last year: EUR 237 million), which is below the previous quarter's volume, as expected. In the Green Hydrogen (gH2) segment with alkaline water electrolysis (AWE) technology, sales of EUR 103 million (same quarter last year: EUR 134 million) and in the Chlor-Alkali (CA) segment of EUR 81 million (same quarter last year: EUR 103 million).

Based on preliminary, unaudited figures, the electrolysis specialist expects consolidated earnings before interest and taxes (EBIT) of EUR 0 million for the third quarter of the current 2024/2025 fiscal year (same quarter last year: EUR 2 million). EBIT in the gH2 segment is expected to have risen to EUR –13 million (prior-year quarter: EUR –23 million). EBIT in the CA segment amounted to EUR 13 million (same quarter last year: EUR 25 million). In the same period last year, one-time effects had caused EBIT in the chlor-alkali segment to rise sharply.

In the first nine months of 2024/25, thyssenkrupp nucera's consolidated sales increased to EUR 663 million (same period last year: EUR 609 million), with the gH2 segment expected to contribute EUR 377 million (prior-year period: EUR 350 million) and the CA segment EUR 286 million (prior-year period: EUR 259 million).

Consolidated EBIT improved in the first nine months of the current fiscal year 2024/2025 to an estimated EUR 4 million (same period last year: EUR –13 million). EBIT in the gH2 segment was EUR –39 million (same period last year: EUR –61 million) and EUR 43 million (same period last year: EUR 47 million) in the CA segment.

Order intake in the third quarter of 2024/25 amounted to EUR 63 million (prior-year period: EUR 271 million). Of this, EUR 13 million was attributable to the gH2 segment (prior-year period: EUR 220 million) and EUR 50 million to the CA segment (same period last year: EUR 51 million). In the same period last year, around EUR 200 million related to the Stegra project in Sweden was recorded in order intake in the Green Hydrogen segment. The total order backlog at Group level amounted to around EUR 0.7 billion as of June 30, 2025.

Against the backdrop of a continuing challenging market environment for green hydrogen with ongoing reluctance to make final investment decisions (FID), the management of thyssenkrupp nucera has adjusted its revenue and EBIT outlook for the full year 2024/2025. The company has also specified its EBIT outlook for the two segments gH2 and CA.

"By specifying our revenue and EBIT outlook for our two segments Green Hydrogen (gH2) and Chlor-Alkali (CA), we are further increasing our transparency. The upward revision of our EBIT guidance underscores our stable operational performance," said Dr. Stefan Hahn, CFO of thyssenkrupp nucera.

The company now expects consolidated sales for the current 2024/2025 fiscal year to be between EUR 850 million and EUR 920 million; the previous outlook was for consolidated sales of between EUR 850 million and EUR 950 million. In the past fiscal year 2023/2024, consolidated sales of EUR 862 million were achieved.

In the gH2 segment, the company now expects sales for the full year 2024/2025 to be between EUR 450 million and EUR 510 million, compared with the previous outlook of EUR 450 million and EUR 550 million. In the 2023/2024 fiscal year just ended, the electrolysis specialist reported revenue of EUR 524 million in the Green Hydrogen (gH2) business segment.

In the Chlor-Alkali segment, management continues to expect sales of between EUR 380 million and EUR 420 million for the current 2024/2025 fiscal year. In the 2023/2024 fiscal year just ended, the company generated sales of EUR 338 million in the Chlor-Alkali segment.

The Management Board has slightly raised its outlook for consolidated EBIT for the 2024/2025 reporting year to between EUR –7 million and EUR 7 million, after previously expecting EBIT of between EUR –30 million and EUR 5 million for the 2024/2025 fiscal year. The electrolysis specialist generated consolidated EBIT of EUR –14 million in the previous reporting year 2023/2024.

For the Green Hydrogen segment, the Executive Board now forecasts EBIT of between EUR –75 million and EUR –55 million for the current fiscal year 2024/2025; previously, EBIT was expected to improve to a negative mid-double-digit million euro amount. In the previous reporting year 2023/2024, thyssenkrupp nucera achieved EBIT of EUR –76 million in the gH2 segment.

The EBIT outlook for the chlor-alkali segment has been raised. Management now expects EBIT of between EUR 55 million and EUR 75 million, after previously expecting positive EBIT in the mid-double-digit million euro range below the previous year's figure. The electrolysis specialist achieved EBIT of EUR 62 million in the chlor-alkali electrolysis segment in the past reporting year 2023/2024.

“By adjusting our outlook within or better than the previous guidance, we are providing a more concrete view of our full-year expectations. We expect a more dynamic order intake trend in both the Green Hydrogen segment and Chlor-Alkali, and our consistent cost management should enable us to continue generating high-margin growth in the future,” said Dr. Werner Ponikwar, CEO of thyssenkrupp nucera.
Photos
Please contact us to inquire about photographs.
Media Inquiries:  

Rita Syre  Senior Media Relations and Financial Relations Manager  Mobil: +49 174 161 86 24 E-Mail: rita.syre@thyssenkrupp-nucera.com

Investor Inquiries:

Dr. Hendrik Finger Head of Investor Relations Phone: +49 231 229 724 347 E-Mail: hendrik.finger@thyssenkrupp-nucera.com

About thyssenkrupp nucera:  
thyssenkrupp nucera offers world-leading technologies for high-efficiency electrolysis plants. The company has extensive in-depth knowledge in the engineering, procurement, and construction of electrochemical plants and a strong track record of more than 600 projects with a total rating of over 10 gigawatts already successfully installed. With its water electrolysis technology to produce green hydrogen, the company offers an innovative solution on an industrial scale for green value chains and an industry fueled by clean energy – a major step towards a climate-neutrality. thyssenkrupp nucera successfully made an IPO in July 2023. The company is a member of the SDAX of the Frankfurt Stock Exchange. 
www.thyssenkrupp-nucera.com
Disclaimer for forward-looking statements
This publication may contain forward-looking statements which address key issues such as strategy, future financial results, events, competitive positions, and product developments. These forward-looking statements – like any business activity in a global environment – are always associated with uncertainty. They are subject to a number of risks, uncertainties, and other factors, including, but not limited to, those described in thyssenkrupp nucera AG & Co. KGaA's ("thyssenkrupp nucera") disclosures. Should one or more of these risks, uncertainties or other factors materialize, or should underlying expectations not occur or should assumptions prove incorrect, the actual results, performances, or achievements of thyssenkrupp nucera may vary materially from those described in the relevant forward-looking statements. Such forward-looking statements may be identified by words such as "expect", "want", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "project" or words of similar meaning. Thyssenkrupp nucera does not intend, nor does it assume any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated.